Last reviewed 2026-04-20 · How we verify

Bendamustin

At a glance

Approved indications

• Chronic lymphoid leukemia, disease
• Diffuse large B-cell lymphoma refractory
• Follicular non-Hodgkin's lymphoma
• Indolent B-Cell Lymphoma
• Treatment prior to tumor-specific T-cell infusion therapy

Common side effects

• Pyrexia
• Nausea
• Vomiting
• Fatigue
• Diarrhea
• Asthenia
• Rash
• Weight decreased
• Hyperuricemia
• Nasopharyngitis
• Pruritus
• Hypersensitivity

Serious adverse events

• Hypertensive crisis
• Pyrexia (Grade 3/4)
• Infection (Grade 3/4)
• Hyperuricemia (Grade 3/4)
• Rash (Grade 3/4)
• Hypersensitivity (Grade 3/4)
• Nausea (Grade 3/4)
• Vomiting (Grade 3/4)
• Diarrhea (Grade 3/4)
• Fatigue (Grade 3/4)

Key clinical trials

• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
• CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
• A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
• A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.